Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug
Investing.com Canada
TD Cowen has initiated coverage on Arcus Biosciences Inc. (NYSE:RCUS) with a Buy rating, citing the potential of its RCC drug, casdatifan, to outperform competitors due to superior target engagement and progression-free survival rates. The firm anticipates strong upcoming data, including 15-month median progression-free survival, which could de-risk Phase III trials and position casdatifan to dominate the over $10 billion renal cell carcinoma market. This positive outlook follows a significant s
Read the full story
This is a short summary. The complete article is published by Investing.com Canada.
Headline and summary aggregated from public news feeds. For information only — not financial advice.